PO.ET01.01 · 实验与分子治疗
Engineering the Next Wave of Antibody-Based Cancer Therapeutics
-
-
-
-
-
- 1761 1761 Tissue Factor expression is associated with B7-H4-mediated immune evasion in ovarian clear cell carcinoma and with response to tisotumab vedotin in preclinical models Yutaro Mori, Ryo Tamura, Kotaro Takahashi, Kosuke Yoshihara
-
- 1763 1763 BSI-737, a best-in-class B7H3xPD-L1 bi-specific ADC with dual function to eliminate tumor via selective killing and exacerbated anti-tumor immune response Hui-Han Hu, Xiaoyao Hao, Yue Gao, Hongyan Li, Jinyu Liu, Jinge Zhao, Yi Lu, Liezhou Ji, Zhigang Ma, Mingjiu Chen, Kedan Lin
- 1764 1764 MC003: A novel bi-epitope, dual-payload, fixed-combination chemoimmunotherapy antibody drug conjugate for the treatment of folate receptor alpha-expressing ovarian cancer Seah H. Lim, Hailiang Zheng, Peipei Zhong
-
-
-
- 1768 1768 High-sensitivity targeted mass spectrometry enables quantification of HLA-presented antigens for TCR-T therapeutic target discovery Simonas Savickas, Anamarija Pfeiffer, Arthur Viodé, Liliana Malinovska, Oliver Bernhardt, Veronique Laforte, Lucy Yang, Roland Bruderer, Daniel Redfern, Yuehan Feng, Wayne Paes
- 1769 1769 LY4170156, an antibody-drug conjugate targeting folate receptor alpha, exhibits enhanced antitumor activity in combination with standard-of-care therapies in preclinical ovarian cancer models Zhaohai Lu, Chun Ping Yu, Jack A. Dempsey, Wei Guo Xu, Lisa Kays, Bonita D. Jones, Andrew Capen, Xueqian Gong
-
- 1771 1771 Synergistic lethality of combination treatment with Trop2-directed antibody-drug conjugate (IMMU-132) and Apo2L/TRAIL in triple negative breast cancer (TNBC) Yonit Addissie, Yoshimi Endo Greer, Stan Lipkowitz
- 1772 1772 HER3-targeted nano-bioparticles deliver 5′-triphosphate-modified FOXC1 siRNA to induce tumor regression and immune activation in HER3⁺ cancers Amirhesam Babajani, Felix Alonso-Valenteen, James Teh, Nelyda Gonzalez, Simoun Mikhael, Michelle Wong, Xiaojiang Cui, Ravinder Abrol, Lali K. Medina-Kauwe
- 1773 1773 Development and characterisation of a novel monoclonal antibody against overexpressed integrin alpha6beta4 on human pancreatic cells Gustavo Arias, Angus G. Dalgleish, Izhar Bagwan, Said Khelwatty, Satvinder Mudan, Tony Walker, Helmout Modjtahedi
-
- 1775 1775 ACR335, a novel cMET/EGFR bispecific dual-payload antibody-drug conjugate, demonstrates potent and broad antitumor activity in preclinical models of solid tumors Zhenwei Miao, Feng Wang, Shanwei Weng, Li Yang, Wu Yao
- 1776 1776 ALK101sc, a novel afucosylated bispecific antibody targeting EGFR and c-MET with common light chain demonstrates potent, broad-spectrum antitumor activity Li Li, Hongwang He, Mengfan Peng, Meiyu Yang, Jiajia Pan, Hui Feng
- 1777 1777 FL116, a PD-1/IL-18 bispecific antibody, enables cis-activation of PD-1⁺ T cells and reshapes the suppressive tumor microenvironment (TME) Haiming Huang, Quanxiao Li, Xiaotuan Zhang, Liwen Ji, Yanling Wu, Dong Wei, Tianlei Ying
